Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21366577 | 0.88 | PIK3CA (0.52) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL2619213 | 0.87 | EGFR (0.50) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL2611054 | 0.81 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL21164389 | 0.80 | PIK3CA (0.48) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL23335615 | 0.78 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL27666530 | 0.78 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL30804805 | 0.77 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL21648655 | 0.75 | EGFR (0.49) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL18713346 | 0.75 | MET (0.34) | MET | |
| SCHEMBL2493571 | 0.75 | EGFR (0.46) | EGFRPIK3CDPIK3CAFGFR4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | EGFR 3433/4885PIK3CD 3168/4885PIK3CA 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.